The Greek experience with efalizumab in psoriasis from a university dermatologic hospital

British Journal of Dermatology

Volumn 156, Issue SUPPL. 2, 2007, Pages 12-16

  Antoniou, C ^a   Stefanaki, I ^a   Stratigos, A ^a   Avgerinou, G ^a   Stavropoulos, P ^a   Potouridou, I ^a   Polidorou, D ^a   Moustou, A E ^a   Kosmadaki, M ^a   Katsambas, A D ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Efalizumab; Psoriasis; Therapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIPYRETIC AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; EMOLLIENT AGENT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

ADD ON THERAPY; ADULT; ANEMIA; ARTHROPATHY; ARTICLE; CANCER; CHILL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; GENERALIZED INFLAMMATORY FLARE; GREECE; HEADACHE; HERPES ZOSTER; HOSPITAL; HUMAN; INFECTION; LEUKOCYTOSIS; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PAPULAR RASH; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RATING SCALE; RISK; SIDE EFFECT; SKIN CANCER; SKIN MANIFESTATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD11A; DERMATOLOGY; FEMALE; FOLLOW-UP STUDIES; GREECE; HOSPITAL DEPARTMENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PSORIASIS; SKIN; TREATMENT OUTCOME;

EID: 33947223261     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.07764.x     Document Type: Article

References (8)

1. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995; 332:581-8.
2. Stern RS, Nijsten T, Feldman SR et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9:136-9.
3. Creamer D, Allen MH, Sousa A et al. Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. Br J Dermatol 1997; 136:859-65.
4. Jullien D, Prinz JC, Langley RG et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 2004; 208:297-306.
5. Gottlieb AB, Hamilton T, Caro I et al. Efalizumab Study Group. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 2006; 54:S154-63.
6. Langley RG, Carey WP, Rafal ES et al. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther 2005; 27:1317-28.
7. Carey W, Glazer S, Gottlieb AB et al. Relapse, rebound, and psoriasis adverse events: an Advisory Group Report. J Am Acad Dermatol 2006; 54:S171-81
8. Hamilton TK. Clinical considerations of efalizumab therapy in patients with psoriasis. Semin Cutan Med Surg 2005; 24:19-27.